NanoViricides Inc. (NNVC)

[Rawnoc]

Development costs charged by and paid to TheraCour Pharma, Inc. were $1,988,046, $2,965,030, and $1,250,901 for the fiscal year ended June 30, 2013, 2012 and 2011, respectively and $8,605,050 since inception. As of June 30, 2013, pursuant to its license agreement, the Company has paid a security advance of $546,783 to and held by TheraCour Pharma, Inc.

TheraCour Pharma, Inc., is affiliated with the Company through the common control of it and our Company by Anil Diwan, President, who is a director of each corporation, and owns approximately 70% of the issued and outstanding common stock of TheraCour Pharma, Inc.



I know, I know....peanuts, right?